NXP800 (CCT361814) is a potent and orally active heat shock factor 1 (HSF1) pathway inhibitor. NXP800 has the potential for cancer research In Vitro NXP800 (example 169) inhibits U20S cells viability (IC 50 =0.056 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo NXP800 (35 mg/kg; po; once daily for 20 days) inhibits the established SK-OV-3 human ovarian cancer solid tumor xenografts grown subcutaneously, with tumor growth inhibition (TGI) of 120% relative to control. Pharmacokinetic AnalysisSpecies Route Dose (mg/kg) T max (h) AUC last (ng·h/mL) Cl tb (mL/min/kg) t 1/2 (h) F (%) AUC u 0-t (h·nM) Free C av 0-24h (nM) Cl u (mL/min/kg) mouse po/iv 5/5 2.0 6000 (7800-4600) (po) 10 (10-9.7) (iv) 4.0 42 (po) 72 3.3 830 (iv) rat po/iv 5/1 6.0 2600 (po) 24 (iv) 3.1 45 (po) 86 3.7 730 (iv) dog po/iv 2.5/0.5 2.0 250 (po) 21 (iv) 1.4 9.1 (po) 35 1.9 150 (iv) MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:HSF1